U.S. Media Stock News

NYSEAM:GROY
NYSEAM:GROYMetals and Mining

Evaluating Gold Royalty (GROY) After A Profit-Making Quarter And Strong Revenue Performance

Gold Royalty (GROY) has attracted attention after reporting first quarter 2026 earnings with sales of US$7.18 million and net income of US$1.77 million, a shift from a loss in the prior year period. See our latest analysis for Gold Royalty. The share price sits at US$3.73, with a 7 day share price return of 5.97% and a 90 day share price return that is down 11.19%. The 1 year total shareholder return of 152.03% indicates strong longer term momentum despite recent volatility and follows...
NasdaqGS:SNDX
NasdaqGS:SNDXBiotechs

Does Expanded Revuforj Leukemia Data Set Change The Bull Case For Syndax Pharmaceuticals (SNDX)?

In early May 2026, Syndax Pharmaceuticals reported first-quarter 2026 revenue of US$64.86 million and a net loss of US$42.67 million, while also highlighting 12 Revuforj (revumenib) abstracts accepted for presentation at the June 2026 European Hematology Association Congress that showcase activity across multiple acute leukemia settings and genetic subtypes. An important angle for investors is the breadth of real-world and combination data for Revuforj, including post-transplant maintenance...
NYSE:DAC
NYSE:DACShipping

Assessing Danaos (DAC) Valuation After Strong Recent Share Price Momentum

Recent performance snapshot Danaos (NYSE:DAC) has attracted fresh attention after recent share price moves, with the stock showing gains over the past month and past 3 months that stand out against its longer term performance profile. With a market value of about US$2.4b and reported revenue of US$1,042.847m alongside net income of US$519.888m, the company’s current pricing invites closer inspection of how investors are weighing its earnings power and risks. See our latest analysis for...
NasdaqGS:BCRX
NasdaqGS:BCRXBiotechs

BioCryst’s Navenibart Deal And Pediatric Data Shape HAE Investment Case

BioCryst Pharmaceuticals (NasdaqGS:BCRX) has granted Neopharmed Gentili exclusive European licensing rights to navenibart for hereditary angioedema. The agreement includes an upfront payment and potential future milestone payments to BioCryst. Neopharmed Gentili is expected to use its existing European commercial infrastructure to support the rollout of navenibart. At ISPOR 2026, BioCryst presented real world evidence on pediatric hereditary angioedema highlighting ongoing medical and...
NasdaqGS:BRKR
NasdaqGS:BRKRLife Sciences

What Bruker (BRKR)'s Mixed Q1 2026 Results and Reaffirmed Guidance Means For Shareholders

Bruker Corporation recently reported first-quarter 2026 results, with sales rising to US$823.4 million from US$801.4 million a year earlier, while net income eased to US$14.4 million, and it reconfirmed full-year 2026 revenue guidance of US$3.57 billion to US$3.60 billion. The combination of higher quarterly sales but lower earnings, alongside unchanged full-year revenue expectations, highlights how Bruker is balancing growth investments and cost pressures as it enters the rest of 2026. We...
NasdaqGS:GLPI
NasdaqGS:GLPISpecialized REITs

A Look At Gaming And Leisure Properties (GLPI) Valuation After Recent Share Price Softness

Recent performance snapshot for Gaming and Leisure Properties (GLPI) Gaming and Leisure Properties (GLPI) has moved quietly on recent trading data, with the stock down 1.5% on the day and 2.2% over the past week, while longer term returns remain positive. See our latest analysis for Gaming and Leisure Properties. At a share price of US$46.97, short term weakness, including a 1-day share price return that declined 1.53% and a 7-day share price return that declined 2.23%, contrasts with a...
NYSE:MTDR
NYSE:MTDROil and Gas

A Look At Matador Resources (MTDR) Valuation After Weaker Q1 2026 Results And Net Loss

Matador Resources (MTDR) is back in focus after first quarter 2026 earnings showed revenue of US$671.64 million and a net loss of US$35.87 million, shifting attention to commodity exposure and capital discipline. See our latest analysis for Matador Resources. Despite the weaker first quarter, the stock is trading at US$57.31 after a recent pullback, with a 90 day share price return of 22.35% and a 5 year total shareholder return of 114.73%. This suggests that longer term momentum has been...
NYSE:PEG
NYSE:PEGIntegrated Utilities

Is Public Service Enterprise Group (PEG) Offering Value After Recent Pullback In Share Price?

If you are wondering whether Public Service Enterprise Group (PEG) stock still offers solid value at current levels, it helps to start with how its recent price and fundamentals line up. The share price closed at US$77.22, with returns that declined 2.7% over the past week and 5.0% over the past month, while sitting up 3.1% over 1 year and 47.2% over 5 years. These figures can influence how investors view both upside potential and risk. Recent news coverage has focused on PEG as a large...
NYSE:DHT
NYSE:DHTOil and Gas

Assessing DHT Holdings (DHT) Valuation After Its Strong First Quarter 2026 Earnings Report

DHT Holdings (DHT) is drawing attention after reporting first quarter 2026 earnings, with revenue of US$186.48 million and net income of US$164.53 million, compared with US$118.57 million and US$44.12 million a year earlier. See our latest analysis for DHT Holdings. Despite strong first quarter results, the share price has recently cooled, with a 1 day share price return of 4.86% down and a 7 day share price return of 5.97% down. Longer term performance, including a year to date share price...
NYSE:ADM
NYSE:ADMFood

A Look At Archer Daniels Midland (ADM) Valuation After Q1 2026 Beat And Raised EPS Outlook

Archer-Daniels-Midland (ADM) is back in focus after better-than-expected Q1 2026 profitability and a higher full-year adjusted EPS outlook, supported by stronger soybean crush, improved ethanol margins, and a recovering Nutrition segment. See our latest analysis for Archer-Daniels-Midland. The Q1 earnings beat and higher full-year guidance have coincided with a sharp pick up in momentum, with a 30-day share price return of 18.7% and year-to-date share price return of 40.4%. In addition, the...
NYSE:MCO
NYSE:MCOCapital Markets

Does AI Disruption Debate and CEO Messaging Shift the Bull Case For Moody's (MCO)?

Moody’s Corporation recently highlighted contrasting views on its long-term resilience to AI disruption, alongside a past appearance by CEO Rob Fauber at the Bernstein Strategic Decisions Conference, where his remarks were broadcast via a live webcast for investors. Together with fresh research arguing Moody’s long-established ratings moat is relatively insulated from AI, and mixed sentiment signals around its shares, these developments are drawing renewed attention to how technology and...
NYSE:PHIN
NYSE:PHINAuto Components

Assessing PHINIA (PHIN) Valuation After Hydrogen Van Debut With Aramco And Upgraded Earnings Forecasts

Why PHINIA’s latest hydrogen milestone matters for stock watchers PHINIA (PHIN) is in focus after debuting its first homologated hydrogen internal combustion light commercial vehicle with Aramco at ACT Expo, while analyst earnings expectations for the company have recently been revised upward. This combination of product progress in lower carbon transportation and shifting earnings expectations provides additional information to consider when looking at how PHINIA’s stock trades today,...
NYSE:LDOS
NYSE:LDOSProfessional Services

Leidos Hypersonics Win Expands Role In High Priority Defense Programs

Leidos Holdings (NYSE:LDOS) has been awarded a U.S. Army contract worth up to $2.7b to move hypersonic weapons programs toward production. The award consolidates several advanced hypersonic efforts under a single umbrella, aimed at accelerating development and deployment. The contract supports the company’s NorthStar 2030 vision by expanding its role in high-priority national defense work. For investors watching Leidos at a share price of $124.17, this hypersonics award arrives after a...
NYSE:KVYO
NYSE:KVYOSoftware

Klaviyo Claude Integration Shifts AI To Execution As Shares Screen Undervalued

Klaviyo (NYSE:KVYO) has launched a deeper integration with Anthropic's Claude through a new Model Context Protocol connector. The update allows marketers to use natural language inside Claude to pull Klaviyo first party data, generate campaigns, and automate multi step workflows. This moves Klaviyo's AI tools from insight generation into direct execution across reporting and campaign creation. Klaviyo is rolling out this Claude integration at a time when the stock is trading at $14.24 and...